Aligos extends South SF HQ lease to 2034
Rhea-AI Filing Summary
Aligos Therapeutics, Inc. (ALGS) entered into a First Amendment to its headquarters lease in South San Francisco with Britannia Biotech Gateway Limited Partnership, extending the lease term from March 31, 2027 to March 31, 2034 and updating rent and flexibility terms.
The amendment sets base monthly rent per rentable square foot at $4.650 from April 1, 2027, escalating annually to $5.716 from April 1, 2033 to March 31, 2034, and requires Aligos to pay a specified percentage of certain landlord expenses. Aligos receives a 10‑month rent abatement from April 1, 2027 to January 31, 2028, subject to no material default. The company gains a one-time option to terminate the lease as of March 31, 2031 by giving notice by March 31, 2030 and paying $2,476,429.22 in termination consideration, plus a separate right to terminate without penalty if it signs a qualifying new lease of at least 60,000 rentable square feet with the landlord or its affiliate. The existing extension option is revised to one seven‑year option following the extended term.
Positive
- None.
Negative
- None.
Insights
Analyzing...
8-K Event Classification
Key Figures
Key Terms
Material Definitive Agreement regulatory
rent abatement financial
termination consideration financial
extension option financial
rentable square feet financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What lease change did Aligos Therapeutics (ALGS) announce on September 10, 2026?
How do base rents change under the new Aligos (ALGS) lease amendment?
Does Aligos Therapeutics (ALGS) receive any rent abatement under the amended lease?
What early termination right does Aligos (ALGS) have in the lease amendment?
What is the penalty-free termination option described for Aligos (ALGS)?
How was the extension option under the Aligos (ALGS) lease revised?
AI-generated analysis. How Rhea-AI works. Not financial advice.